AI Screening Accelerates Heart Failure Clinical Trial Enrollment, Study Shows
Advertisement
Artificial intelligence (AI) can rapidly screen patients for clinical trial enrollment, according to a new study published in JAMA and led by Mass General Brigham researchers. Their novel AI-assisted patient screening tool significantly improved the speed of determining eligibility and enrollment in a heart failure clinical trial compared to manual screening. These findings suggest that using AI can be cheaper than conventional methods and speed up the research process, which could mean patients get earlier access to proven, effective treatments.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.